A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy

As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for multiple metastatic cancers. However, its clinical use is limited by short half-life, low potency, and severe in vivo toxicity. Current IL-2 engineering strategies exhibit evidence of peripheral cytotoxicity. Her...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Nat Commun
Главные авторы: Hsu, Eric J., Cao, Xuezhi, Moon, Benjamin, Bae, Joonbeom, Sun, Zhichen, Liu, Zhida, Fu, Yang-Xin
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2021
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8119481/
https://ncbi.nlm.nih.gov/pubmed/33986267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-22980-w
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы